ALMKT: Sales up 44% in H1 2026, with CellTolerance and U.S. probe growth driving profitability targets
Less than 1 min read
H1 2026 sales grew 44% at constant exchange rates, led by strong U.S. probe sales and rapid international expansion of CellTolerance, which surged 145%. Profitability is targeted by year-end 2027, supported by a strengthened balance sheet and robust sales pipeline.
Original document: Mauna Kea Technologies SA Class O [ALMKT] Earnings Release — Jul. 21 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr